Taiwan Advance Bio-Pharmaceutical Inc. (4186) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiwan Advance Bio-Pharmaceutical Inc. (4186:TWSE), powered by AI.

Current Price
$10.20
Sector
Healthcare
What is the Taiwan Advance Bio-Pharmaceutical Inc. stock price forecast?

Taiwan Advance Bio-Pharmaceutical Inc. is currently trading at $10.20. View real-time AI analysis on Alpha Lenz.

What is Taiwan Advance Bio-Pharmaceutical Inc. insider trading activity?

View the latest insider trading data for Taiwan Advance Bio-Pharmaceutical Inc. on Alpha Lenz.

What is Taiwan Advance Bio-Pharmaceutical Inc.'s P/E ratio?

View Taiwan Advance Bio-Pharmaceutical Inc.'s valuation metrics on Alpha Lenz.

Taiwan Advance Bio-Pharmaceutical Inc.

TWSE · 4186
NT$10.20-0.30(-2.86%)
Ask about Taiwan Advance Bio-Pharmaceutical Inc.'s future dividend policy...
Alpha Chat Insight

Taiwan Advance Bio-Pharmaceutical Inc.'s ROE is 10.4%. Explore profitability and growth together.

Ask for details

Company Overview

Taiwan Advance Bio-Pharmaceutical Inc. is a biotechnology company specializing in the development and production of diagnostic solutions and biopharmaceutical products. The firm provides a diverse range of food safety diagnostic testing kits—including ELISA, rapid, and chemical tests—for applications across sectors such as meat, eggs, aquatic products, dairy, and microorganism analysis. Taiwan Advance Bio-Pharmaceutical also offers customization of test kits, laboratory establishment consulting, and manufactures monoclonal and polyclonal antibodies for research and clinical purposes. Beyond food safety, it supplies abused drugs rapid tests and operates centers for testing and identification of drug abuse, providing both urine and hair-based analyses. The company further delivers cell banking services for the storage of newborn and adult stem cells, underscoring its role in regenerative medicine. Founded in 1989 and based in New Taipei City, Taiwan, Taiwan Advance Bio-Pharmaceutical Inc. has built an international footprint, serving markets in Asia, Europe, and North America. Its integrated approach supports the healthcare and pharmaceutical sectors by enhancing safety, diagnostics, and biotechnological innovation.

SectorHealthcare
IndustryBiotechnology
Employees165

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$364.79MRevenue
0.00Shares Out
165Employees

Margins

64.16%Gross
16.93%EBITDA
10.25%Operating
7.44%Pre-Tax
7.69%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

4.66%Rev 3Yr
9.14%Rev 5Yr
64.48%Op Inc 3Yr
N/AOp Inc 5Yr
106.83%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

3.94%ROA
10.36%ROE
4.73%ROIC

Financial Health

NT$140.74MCash & Cash Equivalents
NT$320.90MNet Debt
161.92%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Taiwan Advance Bio-Pharmaceutical Inc. (ticker: 4186) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 165 employees.

The current price is 10.2 with a P/E ratio of -x and P/B of -x.

ROE is 10.36% and operating margin is 10.25%. Annual revenue is $365M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Taiwan Advance Bio-Pharmaceutical Inc. (4186) Stock Forecast 2026 $10.20 — Price, Financials & Analyst Targets | Alpha Lenz